A Phase 1 interventional study of losartan potassium and Comparator: isosorbide mononitrate (ISMN) in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 58th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 1, and was the 24th registered.
6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 45 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
26 studies in Hypertension by Organon & Co.: none open now, none under way, none of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 26 studies in Hypertension by Organon & Co., this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2006, is one of 2 in phase 1, and was the 18th registered.
Organon & Co.’s Hypertension studies by the year they started, since 1995.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 26 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
losartan 100 mg
Drug: losartan potassium
ISMN 60 mg
Drug: Comparator: isosorbide mononitrate (ISMN)
losartan 100 mg + ISMN 15 mg
Drug: Comparator: losartan + ISMN
losartan 100 mg + ISMN 60 mg
Drug: Comparator: losartan + ISMN
Placebo
Drug: Comparator: Placebo
Single dose losartan 100 mg in one of five treatment periods
Also known as: COZAAR
Single dose ISMN 60 mg in one of five treatment periods
Also known as: IMDUR
Drug pages: Losartan · Isosorbide mononitrate
Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
Drug pages: Losartan · Isosorbide mononitrate
Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
Single dose placebo only in one of five treatment periods
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg
The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.
Time frame: Baseline and 10 hours postdose
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo
The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.
Time frame: Baseline and 10 hours postdose
First Patient Entered: 31-Aug-2006 Last Patient Last Visit: 11-Dec-2006 Number of Sites: 1
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Bp too low for dosing at the next period | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Trial stopped early | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Did not meet criteria for next period | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Completed | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Not completed | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Not taking medication per protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Trial stopped early | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMN | Losartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMN | Losartan + ISMN / Losartan + ISMN / Losartan / ISMN / Placebo | Losartan + ISMN / Placebo / ISMN / Losartan + ISMN / Losartan | Placebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMN | Losartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMN | ISMN / Losartan + ISMN / Losartan + ISMN / Losartan / Placebo | Losartan + ISMN / Placebo / Losartan + ISMN / ISMN / Losartan | Losartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Completed | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.
| Percent Change | Losartan 100 mg + ISMN 60 mg | Losartan 100 mg |
|---|---|---|
| Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg | -24.9 ± 3.8 | -1.8 ± 3.8 |
The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.
| Percent Change | Losartan 100 mg + ISMN 60 mg | Placebo |
|---|---|---|
| Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo | -24.9 ± 3.8 | -1.3 ± 3.8 |
Collected over Run-in period through 14 days post last dose of study drug (documented by telephone contact or in person). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/12 (0%) | 1/12 (8.3%) |
| Losartan 100 mg | — | 0/11 (0%) | 2/11 (18.2%) |
| Losartan 100 mg + ISMN 15 mg | — | 0/13 (0%) | 1/13 (7.7%) |
| Losartan 100 mg + ISMN 60 mg | — | 0/11 (0%) | 4/11 (36.4%) |
| ISMN 60 mg | — | 0/12 (0%) | 4/12 (33.3%) |
| Event | Placebo | Losartan 100 mg | Losartan 100 mg + ISMN 15 mg | Losartan 100 mg + ISMN 60 mg | ISMN 60 mg |
|---|---|---|---|---|---|
| HypotensionVascular disorders | 0/12 | 0/11 | 0/13 | 3/11 | 0/12 |
| HeadacheNervous system disorders | 1/12 | 1/11 | 0/13 | 2/11 | 3/12 |
| NauseaGastrointestinal disorders | 1/12 | 1/11 | 0/13 | 1/11 | 1/12 |
| DizzinessNervous system disorders | 0/12 | 0/11 | 0/13 | 1/11 | 1/12 |
| SomnolenceNervous system disorders | 0/12 | 1/11 | 0/13 | 0/11 | 0/12 |
| Oedema PeripheralGeneral disorders | 0/12 | 0/11 | 1/13 | 0/11 | 0/12 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 0/12 | 0/11 | 1/13 | 0/11 | 0/12 |
| Age, Continuous(years) | All Participants in Study |
|---|---|
| Mean | 57.2 (46 to 67) |
| Sex: Female, Male(Participants) | All Participants in Study |
|---|---|
| Female | 7 |
| Male | 6 |
| Exclusionary Medication Washout(participants) | All Participants in Study |
|---|---|
| Yes | 3 |
| No | 10 |
| Diastolic Blood Pressure(mm Hg) | All Participants in Study |
|---|---|
| Mean | 90.6 (77 to 103) |
| Heart Rate(Beats per Minute) | All Participants in Study |
|---|---|
| Mean | 75.4 (48 to 99) |
| Systolic Blood Pressure(mm Hg) | All Participants in Study |
|---|---|
| Mean | 141.5 (114 to 165) |
No study locations are listed for this record.
The record gives a start of Aug 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Losartan · Isosorbide mononitrate